13
Apr
AtaiBeckley's BPL-003 Shows Rapid, Durable TRD Response on SSRIs
Single intranasal dose of BPL-003 achieved 66.7% antidepressant response by Day 2 in treatment-resistant depression patients on stable SSRIs, with 83% durability at Day 85.
3 min read